MENLO PARK, CA--(MARKET WIRE)--Sep 11, 2007 -- Corcept Therapeutics Incorporated (NasdaqCM:CORT - News) today announced that it has received notification from the Food and Drug Administration (FDA) that the FDA has opened the Investigational New Drug application (IND) for CORLUX for the treatment of Cushing’s Syndrome. CORLUX is a cortisol receptor (GR-II) antagonist.
